Previous Close | 23.94 |
1-Year Change | 250% |
6-Months Change | 71.12% |
3-Months Change | 14% |
Moving Avg (50d) | 23.051 |
Moving Avg (200d) | 18.261 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.63B |
Beta (3-Years) | 2.43 |
Revenue Growth (ttm) | 3676.56% |
Net Profit Margin (ttm) | -13.65% |
Return On Assets (ttm) | -7.82% |
EPS (ttm) | -0.27 |
PE Ratio (ttm) | -88.67 |
Dividend Yield | % |
Asset Description: | TG Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-23 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
24.419 | 25.137 | 25.616 | 26.334 | 27.531 | 28.728 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |